Endpoints News – Biotech, drug, pharma and health news for …
WEBJudge keeps Amgen's $10.7B tax liability suit alive. A New York federal judge has denied Amgen’s motion to dismiss a class action lawsuit alleging the company ...
News – Endpoints News
WEBThe Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry. Yesterday.
Endpoints at #JPM22 - A look at what's to come in 2022
WEBEndpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. For #JPM22, Endpoints is expanding on our proud tradition with multiple panels addressing the most important issues in biopharma R&D. title sponsor.
Endpoints at #BIO23: The dawn of a new biotech era
WEBThe dawn of a new biotech era. The biotech industry’s annual trade conference is back in Boston. We assess where we are as an industry and break down the future trends in biopharma. Featuring conversations on dealmaking, pipeline trends, biotech funding, and more — plus a focus on what the mid-year outlook holds. Register to watch.
Agenda: Endpoints at #JPM24
WEBTop predictions for biotech in 2024. Catalent CEO Alessandro Maselli will be back at the big JPM healthcare confab to talk with Endpoints News founder John Carroll about their top predictions of what’s coming up for the biotech industry in 2024. The stakes couldn’t be higher as the industry grapples with headwinds and new opportunities in a ...
Endpoints at #JPM24 | Primed to unlock biopharma's next …
WEBThe Endpoints Hub will be open for coworking & networking — power up your devices, check email and grab coffee and a bite between session. On Tuesday, you’ll go to biotech downturn survival school, hear about the data private investors expect to see in a tricky capital market and find out the future plans for pharma from top execs in the ...
About Endpoints News – Endpoints News
WEBJohn D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 20 years. Aside from ...
Big dreams dominate among next-gen biotech players
WEBSep 22, 2024 — The Endpoints 11: Big dreams dominate among next-gen biotech players | Live Event + Livestream. Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or go ...
Endpoints 11 - Biopharma's Most Promising Startups in 2021
WEBSep 22, 2024 — The biotech 2.0 era has arrived. And with that backdrop, we'll unveil the top 11 companies supercharging a new generation of startups in 2021. Watch John Carroll & John Chiminski as they talk biotech with the teams behind the winning companies and learn what defines the Endpoints 11.
ESMO23 | Cancer breakthroughs and barriers in oncology R&D
WEBAfter a decade of patient breakthroughs leveraging technologies like immunotherapy, ADCs and targeted therapies, cancer R&D is staring down its next era. Our expert panel will look at how the R&D landscape has shifted, new attempts to go after cancer's “undruggable” targets and how the field is thinking about where the goalposts are in what ...